Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 4 | BMC Psychiatry

Fig. 4

From: The association between maximal muscle strength, disease severity and psychopharmacotherapy among young to middle-aged inpatients with affective disorders – a prospective pilot study

Fig. 4

Maximal muscle strength correlates with inhibiting but not activating medication. A: Summary graphs of the relative dosage of activating (rDAM, white box) and inhibiting medication (rDIM, light grey, p = .043, after Tukey correction, Friedman test) as well as the difference of both relative dosages, the total relative dosage (rTD, dark grey), during the study course (N = 61). B: Summary graphs of relative total maximal muscle strength ( rTFmax) and the relative dosage of the inhibiting medication (rDIM, left panel) as well as activating medication (rDAM, right panel) at t1. Pearson’s correlation coefficient r was calculated. Horizontal lines in boxplots represent median, dotted horizontal lines represent mean; boxes 25th and 75th quartiles; whiskers 5th and 95th percentiles; scatter plots show individual data points. Asterisks indicate significance level (*p < .05, **p < .01, ***p < .001)

Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us